Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Long-Term Deferred Tax (2017 - 2023)

Aytu Biopharma has reported Long-Term Deferred Tax over the past 4 years, most recently at $100000.0 for Q2 2023.

Quarterly Long-Term Deferred Tax changed N/A to $100000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Jun 2023, changed N/A year-over-year, with the annual reading at $100000.0 for FY2023, N/A changed from the prior year.
Long-Term Deferred Tax was $100000.0 for Q2 2023 at Aytu Biopharma, down from $23.3 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $23.3 million in Q2 2019 and troughed at $100000.0 in Q2 2023.